

# Invite



## Looking beyond symptoms - is engagement a future treatment goal for patients with MDD and schizophrenia?

Chaired by: Philip Gorwood, France

Industry Satellite Symposium on the occasion of the 33<sup>rd</sup> ECNP Congress *Virtual*,  
with educational financial support provided by  
Otsuka Pharmaceutical Development & Commercialization Inc. and H. Lundbeck A/S

**ISS.08** (Room 1)

**Date:** Monday 14<sup>th</sup> September 2020

**Time:** 17:30-19:00

### Programme

17:30-17:35	Chairman's welcome	<b>Philip Gorwood</b> France
17:35-17:50	What are the goals and perspectives of treatment in MDD and schizophrenia?	<b>Ilaria Cuomo</b> Italy
17:50-18:05	How can adjunctive treatment improve outcomes for patients with MDD?	<b>Michael Thase</b> USA
18:05-18:20	Do clinical data in schizophrenia reflect expanded treatment goals?	<b>Philip Gorwood</b> France
18:20-18:35	Can we raise the bar for future treatment goals and find a way to measure engagement?	<b>Roger McIntyre</b> Canada
18:35-19:00	Live Q&A	<b>Led by Philip Gorwood</b>



The European Accreditation Committee in CNS (EACIC) has granted 2 CME credits to this satellite symposium. Those interested in obtaining these CME credits will be required to fill in an on-line feedback rating form